TABLE 1.
Clinical and demographic characteristics (N = 51)
| Gender, n (%) | |
|---|---|
| Male | 25 (49%) |
| Female | 26 (51%) |
| Age (years) | |
| Mean (±SD) | 66.2 (±14.6) |
| Range | 31–93 |
| Time from onset to test (days) | |
| Mean (±SD) | 29.3 (±13.3) |
| Range | 1–54 |
| Smokers, n (%) | 16 (31%) |
| Subjective hyposmia, n (%) | 13 (26%) |
| Subjective taste alteration, n (%) | 19 (37%) |
| Symptoms, n (%) | |
| Fever | 45 (88%) |
| Cough | 29 (57%) |
| Dyspnea | 37 (73%) |
| Diarrhea | 4 (8%) |
| Headache | 4 (8%) |
| Myalgia | 8 (16%) |
| Diagnostics, n (%) | |
| Chest RX/CT scan | 42 (82%) |
| Echo B‐lines | 42 (82%) |
| Positive walking test | 40 (78%) |
| Pulmonary thromboembolism | 4 (8%) |
| Laboratory examinations, n (%) | |
| Leukopenia/lymphopenia | 28 (55%) |
| High LDH | 43 (84%) |
| High transaminases | 17 (33%) |
| High gammaGT | 6 (12%) |
| High CPK | 9 (18%) |
| High D‐dimer | 34 (67%) |
| Medical treatments, n (%) | |
| Hydroxychloroquine | 44 (86%) |
| Azithromycin | 42 (82%) |
| Steroids | 28 (55%) |
| LMWH | 49 (96%) |
| Tocilizumab | 25 (49%) |
| Anakinra | 3 (6%) |
| Remdesivir | 3 (6%) |
| Respiratory support, n (%) | |
| None | 10 (20%) |
| Low/high flow oxygen | 13 (25%) |
| NIV | 15 (30%) |
| Intubation and IMV | 13 (25%) |
| Clinical recovery at test, n (%) a | 23 (45%) |
| Time from clinical recovery to test (days) | |
| Mean (±SD) | 7.7 (±7.3) |
| Range | 1–28 |
| Viral clearance at test, n (%) b | 20 (39%) |
| Time from viral clearance to test (days) | |
| Mean (±SD) | 7.0 (±5.9) |
| Range | 1–22 |
LDH, lactate dehydrogenase; GammaGT, gamma‐glutamyltransferase; CPK, creatine phosphokinase; LMWH, low‐molecular‐weight heparin; NIV, noninvasive ventilation; IMV, invasive mechanical ventilation.
a
Clinical recovery: Patients were considered clinically recovered if had no fever, respiratory rate < 22 apm, and peripheral blood oxygenation > 94% without oxygen implementation for the last 72 hr.
b
Viral clearance: Patients were considered virus‐free after two consecutive negative SARS‐CoV‐2 RT‐PCR assays on rhinopharyngeal swabs, separated by at least 24 hr.